Overview

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Status:
Recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production.

Phase:

Phase 1

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Pembrolizumab